Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17453391 | 0.87 | UTS2R (0.43) | UTS2RACHEERBB2PTK6RXFP1 | |
| SCHEMBL17453374 | 0.81 | UTS2R (0.54) | UTS2RERBB2PTK6KDM4ERXFP1 | |
| SCHEMBL20462060 | 0.77 | IGF1R (0.39) | UTS2RERBB2PTK6KDM4EALDH1A1 | |
| SCHEMBL2628322 | 0.76 | ACHE (0.54) | UTS2RACHEBCHEGAAL3MBTL1 | |
| SCHEMBL16011809 | 0.76 | ALK (0.54) | UTS2RERBB2PTK6GABRA1GABRG2 | |
| SCHEMBL2628367 | 0.73 | ACHE (0.56) | UTS2RACHEBCHEGAAL3MBTL1 | |
| SCHEMBL23885302 | 0.72 | KDM4E (0.48) | UTS2RACHEGAAL3MBTL1KDM4E | |
| SCHEMBL28593610 | 0.71 | ADORA3 (0.53) | KDM4EALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL17453368 | 0.71 | DYRK1A (0.52) | ACHEBCHEERBB2PTK6KDM4E | |
| SCHEMBL4962608 | 0.70 | ALK (0.37) | UTS2RERBB2PTK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325908-B2 | CaMKII inhibitors and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3189052-B1 | CAMKII INHIBITORS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3189052-B1 | CAMKII INHIBITORS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20200385383-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10759792-B2 | CaMKII inhibitors and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-2964225-B1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9951061-B2 | CaMKII inhibitors and uses thereof | ALLOSTEROS THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| WO-2016037106-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20160024078-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325908-B2 | CaMKII inhibitors and uses thereof | CAMK2G, CAMK2B, CAMK1 | UTS2R 4564/4885ACHE 1142/4885BCHE 2418/4885 |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | UTS2R 4564/4885ACHE 1142/4885BCHE 2418/4885 |
| US-20160024078-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | UTS2R 4564/4885ACHE 1142/4885BCHE 2418/4885 |
| US-20200385383-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | UTS2R 4564/4885ACHE 1142/4885BCHE 2418/4885 |
| US-10759792-B2 | CaMKII inhibitors and uses thereof | CAMK2G, CAMK2B, CAMK1 | UTS2R 4564/4885ACHE 1142/4885BCHE 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.